Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962407 | 0.85 | FFAR2 (0.38) | FFAR2LMNA | |
| SCHEMBL21542758 | 0.78 | FFAR2 (0.35) | FFAR2LMNA | |
| SCHEMBL29832003 | 0.77 | GALR3 (0.35) | HTTRAB9AGALR3GAAMAPT | |
| SCHEMBL28855943 | 0.77 | GALR3 (0.35) | HTTRAB9AGALR3GAAMAPT | |
| SCHEMBL41301 | 0.72 | — | — | |
| SCHEMBL22720430 | 0.71 | NOS3 (0.32) | — | |
| SCHEMBL29614779 | 0.71 | NOS3 (0.32) | — | |
| SCHEMBL25887298 | 0.68 | FFAR2 (0.30) | FFAR2 | |
| SCHEMBL28855951 | 0.68 | ALDH1A1 (0.43) | HTTRAB9AGAAMAPTLMNA | |
| SCHEMBL21542912 | 0.68 | FFAR2 (0.36) | HTTFFAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-06 | — | — | US | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240083913-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2024-03-14 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| US-20240043448-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2024-02-08 | — | — | US | disclosed |
| CN-114867726-B | Small molecule inhibitors of KRAS G12C mutants | 默沙东有限责任公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-05-06 | — | — | US | disclosed |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2021-04-29 | — | — | US | disclosed |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2021-04-29 | — | — | US | disclosed |
| EP-3807276-A2 | KRAS G12C INHIBITORS ENCOMPASSING A PIPERAZINE RING AND USE THEREOF IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2021052499-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112159405-A | Pyridopyrimidinone compounds and application thereof | 广州必贝特医药技术有限公司 | 2021-01-01 | — | — | CN | disclosed |
| WO-2019243533-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | HTT 3295/4885FFAR2 4272/4885RAB9A 34/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HTT 2514/4885FFAR2 4110/4885RAB9A 70/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HTT 2514/4885FFAR2 4110/4885RAB9A 70/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | HTT 2076/4885FFAR2 3322/4885RAB9A 143/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HTT 2514/4885FFAR2 4110/4885RAB9A 70/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HTT 2514/4885FFAR2 4110/4885RAB9A 70/4885 |
| US-20240083913-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | HTT 3295/4885FFAR2 4272/4885RAB9A 34/4885 |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | HTT 3295/4885FFAR2 4272/4885RAB9A 34/4885 |
| US-20240043448-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | HTT 3295/4885FFAR2 4272/4885RAB9A 34/4885 |
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | HTT 33/4885FFAR2 4772/4885RAB9A 2809/4885 |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | HTT 3476/4885FFAR2 4291/4885RAB9A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.